









CORRECTION OPEN



# Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P. Sharman , Miklos Egyed, Wojciech Jurczak , Alan Skarbnik, John M. Pagel , Ian W. Flinn , Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre , George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia , Ann Janssens, Florence Cymbalista, Jennifer A. Woyach , Emmanuelle Ferrant, William G. Wierda , Veerendra Munugalavadla, Ting Yu, Min Hui Wang and John C. Byrd

© The Author(s) 2024

*Leukemia* (2025) 39:529; <https://doi.org/10.1038/s41375-024-02487-1>

Correction to: *Leukemia* <https://doi.org/10.1038/s41375-021-01485-x>, published online 01 January 2022

The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

© The Author(s) 2024